FRAME

Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Retrieved on: 
Wednesday, December 13, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, NDA, Paclitaxel, Woman, Institute of Cancer Research, Research, Safety, Food, Avutometinib, Cancer, Letrozole, Disease, Verastem Oncology, Patient, Anastrozole, GOG, PFS, Consultant, RAMP, Breakthrough therapy, Part, FDA, NHS foundation trust, FRAME, ORR, The Institute, Ovarian cancer, FRCP, Doctor of Philosophy, Physician, Accelerated approval (FDA), Royal Marsden Hospital, Pharmaceutical industry, MBBS, Topotecan

“Patients and treating physicians have advocated for more research and development in support of LGSOC.

Key Points: 
  • “Patients and treating physicians have advocated for more research and development in support of LGSOC.
  • At Verastem Oncology, we are moving with urgency to offer a Phase 3 study specifically directed at this disease in an effort to address this need,” said Dan Paterson, President and Chief Executive Officer, Verastem Oncology.
  • RAMP 301 is a global trial with enrollment open in the U.S. and planned enrollment in Canada, the United Kingdom, Europe, Australia, and Korea.
  • Dr. Grisham and Dr. Banerjee are paid consultants for Verastem Oncology.

Groundbreaking Innovations Unveiled: Winners Announced for the AI3 Prize Competition

Retrieved on: 
Friday, November 17, 2023
Software, Mobile, Wireless, Networks, Internet, Hardware, Technology, Other Education, Continuing, Artificial Intelligence, University, Security, Education, Motivation, Texas A&M University, ChatGPT, Safety, Internet of things, AI3, Creativity, Artificial intelligence, Algorithm, TEEX, FRAME, Engineering, AI, NIST, Government, Transport, Big data, Television, Customer service, Emergency

After rigorous evaluation and live demonstrations at TEEX Disaster City®, two teams, CNA-riis and Engineering Dynamics, emerged as the 1st place winners of the AI3 Prize Competition.

Key Points: 
  • After rigorous evaluation and live demonstrations at TEEX Disaster City®, two teams, CNA-riis and Engineering Dynamics, emerged as the 1st place winners of the AI3 Prize Competition.
  • “Winning the AI3 competition is incredibly exciting and fills our CNA-RIIS team with motivation to face new challenges,” said CNA Research Analyst John Crissman.
  • The AI3 Prize Competition challenged contestants to develop a solution that would generate user-friendly real-time data visualizations by integrating information from IoT sensors and other known and unknown sources.
  • "We are proud of the collaborative spirit that has driven the success of the AI3 Prize Competition,” said Mojdeh Mahdavi, from US Ignite.

Verastem Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Wednesday, November 8, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Standard of care, NSCLC, Food, Pancreas, Anastrozole, Regulatory affairs, Ovarian cancer, GAAP, Pancreatic Cancer Action Network, Paclitaxel, Accelerated approval (FDA), ORR, European Network of Transmission System Operators for Electricity, Safety, Cancer, Therapy, Investment, Patient, General Administration of Sport of China, Verastem Oncology, Topotecan, Conference, Bank statement, Clinical trial, FRAME, Travel, Letrozole, RAMP, FDA, SOC, AACR, RAS, Research and development, The Annual Global Orgasm for Peace, GOG, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, KRAS, Senior, Pharmacokinetics, European Society of Gynaecological Oncology, Lung cancer, Table, Diagnosis, Pharmaceutical industry, Bank, Finance

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the third quarter ending September 30, 2023 and highlighted recent progress.

Key Points: 
  • Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the third quarter ending September 30, 2023 and highlighted recent progress.
  • Verastem Oncology ended the third quarter of 2023 with cash, cash equivalents and investments of $165.7 million.
  • Research & development expenses for the 2023 Quarter were $13.9 million, compared to $11.3 million for the 2022 Quarter.
  • Selling, general & administrative expenses for the 2023 Quarter were $7.4 million, compared to $6.4 million for the 2022 Quarter.

Verastem Oncology Announces Efficacy and Safety Data of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in Heavily Pretreated Patient Population

Retrieved on: 
Monday, November 6, 2023
Research, General Health, Pharmaceutical, Oncology, Consumer, Clinical Trials, Science, Women, Biotechnology, FDA, Other Science, Health, Ovarian cancer, RAMP, Standard of care, SOC, Topotecan, Food, Lot, Soda Springs, The Annual Global Orgasm for Peace, Safety, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, Paclitaxel, Disease, Memorial Sloan Kettering Cancer Center, FRAME, ORR, Letrozole, RECIST, Part, Cancer, Patient, Anastrozole, Verastem Oncology, Pharmaceutical industry

Verastem Oncology (Nasdaq: VSTM) (the “Company”), a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced today results of the efficacy and safety of avutometinib and defactinib in recurrent low-grade serous ovarian cancer (LGSOC) following prior systemic therapy.

Key Points: 
  • Verastem Oncology (Nasdaq: VSTM) (the “Company”), a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced today results of the efficacy and safety of avutometinib and defactinib in recurrent low-grade serous ovarian cancer (LGSOC) following prior systemic therapy.
  • The analysis also evaluated efficacy in the context of best response to most recent prior treatment in the metastatic/recurrent setting.
  • The safety profiles of avutometinib and defactinib were similar in the less and more heavily pretreated subgroups and both analyses were consistent with previously reported safety data.
  • Dr. Grisham is a paid consultant for Verastem Oncology.

NORDSTROM AND NORDSTROM RACK INVITE YOU HOME FOR THE HOLIDAYS

Retrieved on: 
Monday, October 30, 2023
Gift, Wollman Rink, Pet, MAC, Nordstrom Downtown Seattle, The Walt Disney Company, Customer service, Music, Carbone, Beauty, Swarovski, Sale, Homesick, My Little Pony: Best Gift Ever, Hawk's Nest, New York, Personalization, Lego, Magic, Pajamas, Imagination, AllSaints, Lucy Wainwright Roche, Drybar, Shoe, The North Face, Barbour, Love, Woman, Dyson, Letter, New York City Department of Parks and Recreation, Centennial, Holiday, System, Coffee, Open Edition, Cyber Monday, Friends, Nordstrom Rack, Printing, Department store, Online shopping, Mail order, Fashion design, Amusement park, Nordstrom, Mattel, UGG, Cast, Theory, FRAME, J.Crew

SEATTLE, Oct. 30, 2023 /PRNewswire/ -- In this season of joy, Nordstrom and Nordstrom Rack are inviting you home for the holidays. This year, Nordstrom and Nordstrom Rack are the ultimate holiday gifting destinations offering everything you need in a range of prices for everyone you love – including yourself. From extraordinary gifts to stocking stuffers, to exclusive Disney100 and Swarovski pop-ups to festive experiences, we're here to help, making it easy with our services, including our online wish list function, same-day and next-day order pick up, personalization, and our amazing salespeople who can help customers find the very best gifts.

Key Points: 
  • Simply choose Same-Day or Next-Day Pick Up when completing your online order and select the Nordstrom, Nordstrom Local or Nordstrom Rack store where you'd like to pick up your order.
  • For gift wrapping, Nordstrom will charge $5 per item purchased at Nordstrom and Nordstrom Rack and $15 for any non-Nordstrom or Nordstrom Rack item.
  • Visit any Nordstrom or Nordstrom Local and select Nordstrom Rack stores to give your gifts a personalized touch.
  • Shop the best beauty and grooming gifts from Nordstrom and Nordstrom Rack – and if you're a Nordy Club member, earn 5X the points while doing it.

Verastem Presents Avutometinib and Defactinib Combination Program Updates at the 5th Annual RAS-Targeted Drug Development Summit

Retrieved on: 
Thursday, September 28, 2023
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, KRAS, FRCP, Verastem Oncology, MBBS, American Society of Clinical Oncology, Clinical trial, Cancer, Breakthrough therapy, Royal Marsden Hospital, The Institute, DNB, FRAME, Part, Doctor of Philosophy, PFS, ASCO, RAMP, RAS, Patient, Annual general meeting, Drug development, Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Society, ORR, RAF, Pharmaceutical industry, MD

Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the presentation of scientific background and clinical trial updates on the avutometinib and defactinib programs at the 5th Annual RAS-Targeted Drug Development Summit in Boston, Massachusetts.

Key Points: 
  • Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the presentation of scientific background and clinical trial updates on the avutometinib and defactinib programs at the 5th Annual RAS-Targeted Drug Development Summit in Boston, Massachusetts.
  • The updates are part of two oral presentations by Jonathan Pachter, PhD, Chief Scientific Officer and Louis Denis, MD, Chief Medical Officer at Verastem Oncology.
  • The first presentation titled “Vertical Inhibition of RAS, RAF & MEK: Enhancing Antitumor Efficacy of KRAS G12C & G12D Inhibitors with RAF/MEK Clamp Avutometinib”, includes scientific rationale for clinical combinations with avutometinib and defactinib in various RAS pathway-driven cancers.
  • The second presentation titled, “Introducing Rational Combinations of RAF/MEK Clamp Avutometinib: Breakthrough Therapy Designation & Beyond,” discusses novel combination treatment approaches and provides an overview of the avutometinib and defactinib clinical development program.

Verastem Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Tuesday, August 8, 2023
Research, FDA, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Topotecan, Pancreatic cancer, KRAS, Verastem Oncology, Avutometinib, Table, BIW, Pancreatic Cancer Action Network, Bank statement, General Administration of Press and Publication, Pancreas, Cancer, Paclitaxel, Anastrozole, GAAP, SOC, NSCLC, FRAME, Lung cancer, PFS, RAMP, Acquisition, HIV disease progression rates, RAS, Patient, Standard of care, Investment, European Society of Gynaecological Oncology, GOG, European Network of Transmission System Operators for Electricity, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Research and development, Society, Breakthrough, ORR, Letrozole, Food, Safety, Pharmaceutical industry, Transformer

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the second quarter ending June 30, 2023 and highlighted recent progress.

Key Points: 
  • Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the second quarter ending June 30, 2023 and highlighted recent progress.
  • Verastem Oncology ended the second quarter of 2023 with cash, cash equivalents and investments of $183.1 million.
  • Research & development expenses for the 2023 Quarter were $12.9 million, compared to $14.9 million for the 2022 Quarter.
  • Selling, general & administrative expenses for the 2023 Quarter were $7.4 million, compared to $6.5 million for the 2022 Quarter.

Verastem Oncology Announces Design for Confirmatory Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Retrieved on: 
Wednesday, July 5, 2023
Biotechnology, FDA, Health, Philanthropy, Pharmaceutical, Oncology, Other Science, Research, Foundation, Science, Clinical Trials, FRCP, Verastem Oncology, MBBS, Avutometinib, Ovarian cancer, Cancer, Paclitaxel, Food, Royal Marsden Hospital, SOC, FRAME, Part, PFS, Accelerated approval (FDA), ORR, RAMP, Patient, Standard of care, Investment, MA, Institute of Cancer Research, European Society of Gynaecological Oncology, GOG, European Network for the Investigation of Gender Incongruence, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Letrozole, Safety, Pharmaceutical industry, MD

RAMP 301, a randomized global confirmatory trial, will evaluate the efficacy and safety of avutometinib and defactinib versus standard of care (SOC) chemotherapy and hormonal therapy in patients with recurrent LGSOC.

Key Points: 
  • RAMP 301, a randomized global confirmatory trial, will evaluate the efficacy and safety of avutometinib and defactinib versus standard of care (SOC) chemotherapy and hormonal therapy in patients with recurrent LGSOC.
  • RAMP 301 is the follow-up confirmatory study for full approval in recurrent LGSOC.
  • The RAMP 301 trial will be led globally and in the U.S. by Rachel Grisham, MD, Section Head, Ovarian Cancer and Director, Gynecologic Medical Oncology at Memorial Sloan Kettering Cancer Center in Westchester, NY.
  • Dr. Banerjee and Dr. Grisham have consulting relationships with Verastem Oncology.

Peterson Group Breaks Ground on FRAME, Bringing 217 Homes to Vancouver’s Most Well-Connected Corridor

Retrieved on: 
Tuesday, July 4, 2023
Yee, Metro, Downtown, Peterson (company), North Earl Street, Queen Elizabeth Park, Collection, Transport, Tunnel, Metrotown, FRAME, Development

A groundbreaking celebration took place to mark this significant project milestone that will see 217 much-needed homes take shape in Vancouver’s most well-connected urban core.

Key Points: 
  • A groundbreaking celebration took place to mark this significant project milestone that will see 217 much-needed homes take shape in Vancouver’s most well-connected urban core.
  • Nestled at the intersection of Kingsway and Earles, Peterson Group's FRAME community perfectly aligns with this vision.
  • “We see the long-term potential of the Norquay Village Neighbourhood Centre Plan and evolution of the Kingsway Corridor,” says Brendan Yee, Director, Development, Peterson Group.
  • With full control of the project, Peterson Group has construction well underway at FRAME.

Updated Data from Part A of Verastem Oncology's RAMP 201 Trial Show an Objective Response Rate of 45% in Patients with Recurrent Low-Grade Serous Ovarian Cancer Treated with Avutometinib and Defactinib

Retrieved on: 
Thursday, May 25, 2023
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, KRAS, Bevacizumab, FRCP, Verastem Oncology, MBBS, Avutometinib, Diarrhea, Xeroderma, Ovarian cancer, Safety, Survival, Cancer, PO, Woman, Royal Marsden Hospital, The Institute, FRAME, MEK, CPK, Rash, EMA, ORR, Vomiting, Peripheral edema, RAMP, Patient, Blood, Memorial Sloan Kettering Cancer Center, NHS foundation trust, MA, Nausea, Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, Breakthrough, Food, Fatigue, Pharmaceutical industry, Medical device, Part

In the RAMP 201 study, treatment with the combination of avutometinib and defactinib resulted in an objective response rate (ORR) of 45% (13/29) and tumor shrinkage in 86% (25/29) of evaluable patients.

Key Points: 
  • In the RAMP 201 study, treatment with the combination of avutometinib and defactinib resulted in an objective response rate (ORR) of 45% (13/29) and tumor shrinkage in 86% (25/29) of evaluable patients.
  • RAMP 201 is an international registration-directed Phase 2 study evaluating the safety and efficacy of avutometinib (VS-6766) alone and in combination with defactinib among patients with recurrent LGSOC.
  • The discontinuation rate, due to ≥ 1 adverse event, was 12% in the trial overall to date (4.9% due to elevated blood CPK).
  • These results indicate that the combination of avutometinib and defactinib shows promise as a tolerable treatment with impressive response rates for women with recurrent LGSOC.